The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Viral Vectors and Plasmid DNA Manufacturing Market Research Report 2025
Synopsis
The viral vectors and plasmid DNA is used for the treatment of cancers, inherited disorders, viral infections and other diseases.
The global Viral Vectors and Plasmid DNA Manufacturing market was valued at US$ 608 million in 2023 and is anticipated to reach US$ 1961.9 million by 2030, witnessing a CAGR of 18.0% during the forecast period 2024-2030.
Global Viral Vectors and Plasmid DNA Manufacturing key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Asia-Pacific, and Europe, both have a share over 40 percent.
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections , etc.
This report aims to provide a comprehensive presentation of the global market for Viral Vectors and Plasmid DNA Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vectors and Plasmid DNA Manufacturing.
Report Scope
The Viral Vectors and Plasmid DNA Manufacturing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Viral Vectors and Plasmid DNA Manufacturing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vectors and Plasmid DNA Manufacturing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BioReliance
Cobra Biologics
Oxford BioMedica
UniQure
FinVector
MolMed
MassBiologics
Richter-Helm
FUJIFILM Diosynth Biotechnologies
Lonza
Aldevron
Eurogentec
Cell and Gene Therapy Catapult
Biovian
Thermo Fisher Scientific (Brammer Bio)
VGXI
PlasmidFactory
Segment by Type
Plasmid DNA
Viral Vectors
Segment by Application
Cancers
Inherited Disorders
Viral Infections
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral Vectors and Plasmid DNA Manufacturing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The viral vectors and plasmid DNA is used for the treatment of cancers, inherited disorders, viral infections and other diseases.
The global Viral Vectors and Plasmid DNA Manufacturing market was valued at US$ 608 million in 2023 and is anticipated to reach US$ 1961.9 million by 2030, witnessing a CAGR of 18.0% during the forecast period 2024-2030.
Global Viral Vectors and Plasmid DNA Manufacturing key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Asia-Pacific, and Europe, both have a share over 40 percent.
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections , etc.
This report aims to provide a comprehensive presentation of the global market for Viral Vectors and Plasmid DNA Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vectors and Plasmid DNA Manufacturing.
Report Scope
The Viral Vectors and Plasmid DNA Manufacturing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Viral Vectors and Plasmid DNA Manufacturing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vectors and Plasmid DNA Manufacturing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
BioReliance
Cobra Biologics
Oxford BioMedica
UniQure
FinVector
MolMed
MassBiologics
Richter-Helm
FUJIFILM Diosynth Biotechnologies
Lonza
Aldevron
Eurogentec
Cell and Gene Therapy Catapult
Biovian
Thermo Fisher Scientific (Brammer Bio)
VGXI
PlasmidFactory
Segment by Type
Plasmid DNA
Viral Vectors
Segment by Application
Cancers
Inherited Disorders
Viral Infections
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral Vectors and Plasmid DNA Manufacturing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Plasmid DNA
1.2.3 Viral Vectors
1.3 Market by Application
1.3.1 Global Viral Vectors and Plasmid DNA Manufacturing Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cancers
1.3.3 Inherited Disorders
1.3.4 Viral Infections
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Viral Vectors and Plasmid DNA Manufacturing Market Perspective (2019-2030)
2.2 Viral Vectors and Plasmid DNA Manufacturing Growth Trends by Region
2.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Viral Vectors and Plasmid DNA Manufacturing Historic Market Size by Region (2019-2024)
2.2.3 Viral Vectors and Plasmid DNA Manufacturing Forecasted Market Size by Region (2025-2030)
2.3 Viral Vectors and Plasmid DNA Manufacturing Market Dynamics
2.3.1 Viral Vectors and Plasmid DNA Manufacturing Industry Trends
2.3.2 Viral Vectors and Plasmid DNA Manufacturing Market Drivers
2.3.3 Viral Vectors and Plasmid DNA Manufacturing Market Challenges
2.3.4 Viral Vectors and Plasmid DNA Manufacturing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Viral Vectors and Plasmid DNA Manufacturing Players by Revenue
3.1.1 Global Top Viral Vectors and Plasmid DNA Manufacturing Players by Revenue (2019-2024)
3.1.2 Global Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Players (2019-2024)
3.2 Global Viral Vectors and Plasmid DNA Manufacturing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Viral Vectors and Plasmid DNA Manufacturing Revenue
3.4 Global Viral Vectors and Plasmid DNA Manufacturing Market Concentration Ratio
3.4.1 Global Viral Vectors and Plasmid DNA Manufacturing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Viral Vectors and Plasmid DNA Manufacturing Revenue in 2023
3.5 Viral Vectors and Plasmid DNA Manufacturing Key Players Head office and Area Served
3.6 Key Players Viral Vectors and Plasmid DNA Manufacturing Product Solution and Service
3.7 Date of Enter into Viral Vectors and Plasmid DNA Manufacturing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Viral Vectors and Plasmid DNA Manufacturing Breakdown Data by Type
4.1 Global Viral Vectors and Plasmid DNA Manufacturing Historic Market Size by Type (2019-2024)
4.2 Global Viral Vectors and Plasmid DNA Manufacturing Forecasted Market Size by Type (2025-2030)
5 Viral Vectors and Plasmid DNA Manufacturing Breakdown Data by Application
5.1 Global Viral Vectors and Plasmid DNA Manufacturing Historic Market Size by Application (2019-2024)
5.2 Global Viral Vectors and Plasmid DNA Manufacturing Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)
6.2 North America Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)
6.4 North America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)
7.2 Europe Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)
7.4 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)
8.2 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size by Region (2019-2024)
8.4 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)
9.2 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)
9.4 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)
10.2 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)
10.4 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 BioReliance
11.1.1 BioReliance Company Detail
11.1.2 BioReliance Business Overview
11.1.3 BioReliance Viral Vectors and Plasmid DNA Manufacturing Introduction
11.1.4 BioReliance Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
11.1.5 BioReliance Recent Development
11.2 Cobra Biologics
11.2.1 Cobra Biologics Company Detail
11.2.2 Cobra Biologics Business Overview
11.2.3 Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Introduction
11.2.4 Cobra Biologics Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
11.2.5 Cobra Biologics Recent Development
11.3 Oxford BioMedica
11.3.1 Oxford BioMedica Company Detail
11.3.2 Oxford BioMedica Business Overview
11.3.3 Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Introduction
11.3.4 Oxford BioMedica Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
11.3.5 Oxford BioMedica Recent Development
11.4 UniQure
11.4.1 UniQure Company Detail
11.4.2 UniQure Business Overview
11.4.3 UniQure Viral Vectors and Plasmid DNA Manufacturing Introduction
11.4.4 UniQure Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
11.4.5 UniQure Recent Development
11.5 FinVector
11.5.1 FinVector Company Detail
11.5.2 FinVector Business Overview
11.5.3 FinVector Viral Vectors and Plasmid DNA Manufacturing Introduction
11.5.4 FinVector Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
11.5.5 FinVector Recent Development
11.6 MolMed
11.6.1 MolMed Company Detail
11.6.2 MolMed Business Overview
11.6.3 MolMed Viral Vectors and Plasmid DNA Manufacturing Introduction
11.6.4 MolMed Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
11.6.5 MolMed Recent Development
11.7 MassBiologics
11.7.1 MassBiologics Company Detail
11.7.2 MassBiologics Business Overview
11.7.3 MassBiologics Viral Vectors and Plasmid DNA Manufacturing Introduction
11.7.4 MassBiologics Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
11.7.5 MassBiologics Recent Development
11.8 Richter-Helm
11.8.1 Richter-Helm Company Detail
11.8.2 Richter-Helm Business Overview
11.8.3 Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Introduction
11.8.4 Richter-Helm Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
11.8.5 Richter-Helm Recent Development
11.9 FUJIFILM Diosynth Biotechnologies
11.9.1 FUJIFILM Diosynth Biotechnologies Company Detail
11.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.9.3 FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Introduction
11.9.4 FUJIFILM Diosynth Biotechnologies Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
11.9.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.10 Lonza
11.10.1 Lonza Company Detail
11.10.2 Lonza Business Overview
11.10.3 Lonza Viral Vectors and Plasmid DNA Manufacturing Introduction
11.10.4 Lonza Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
11.10.5 Lonza Recent Development
11.11 Aldevron
11.11.1 Aldevron Company Detail
11.11.2 Aldevron Business Overview
11.11.3 Aldevron Viral Vectors and Plasmid DNA Manufacturing Introduction
11.11.4 Aldevron Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
11.11.5 Aldevron Recent Development
11.12 Eurogentec
11.12.1 Eurogentec Company Detail
11.12.2 Eurogentec Business Overview
11.12.3 Eurogentec Viral Vectors and Plasmid DNA Manufacturing Introduction
11.12.4 Eurogentec Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
11.12.5 Eurogentec Recent Development
11.13 Cell and Gene Therapy Catapult
11.13.1 Cell and Gene Therapy Catapult Company Detail
11.13.2 Cell and Gene Therapy Catapult Business Overview
11.13.3 Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Introduction
11.13.4 Cell and Gene Therapy Catapult Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
11.13.5 Cell and Gene Therapy Catapult Recent Development
11.14 Biovian
11.14.1 Biovian Company Detail
11.14.2 Biovian Business Overview
11.14.3 Biovian Viral Vectors and Plasmid DNA Manufacturing Introduction
11.14.4 Biovian Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
11.14.5 Biovian Recent Development
11.15 Thermo Fisher Scientific (Brammer Bio)
11.15.1 Thermo Fisher Scientific (Brammer Bio) Company Detail
11.15.2 Thermo Fisher Scientific (Brammer Bio) Business Overview
11.15.3 Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Introduction
11.15.4 Thermo Fisher Scientific (Brammer Bio) Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
11.15.5 Thermo Fisher Scientific (Brammer Bio) Recent Development
11.16 VGXI
11.16.1 VGXI Company Detail
11.16.2 VGXI Business Overview
11.16.3 VGXI Viral Vectors and Plasmid DNA Manufacturing Introduction
11.16.4 VGXI Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
11.16.5 VGXI Recent Development
11.17 PlasmidFactory
11.17.1 PlasmidFactory Company Detail
11.17.2 PlasmidFactory Business Overview
11.17.3 PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Introduction
11.17.4 PlasmidFactory Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
11.17.5 PlasmidFactory Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
